Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA User Fee Bills: Is It Possible For Reauthorization To Be Too Clean?

Executive Summary

First draft of user fee omnibus bill is about as 'clean' as a bill can be – free of the policy riders that have always been attached to US FDA funding legislation in past cycles. That is good news for industry, which is eager to see the program reauthorized with as little drama as possible, but could the bill actually be too clean?


Related Content

Rhetoric Meets Reality: A Timeline Of Trump's First 100 Days
First Draft FDA User Fee Bill Is Squeaky Clean
Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals
REMS Abuses: Congressional Panel’s Focus Turns To Federal Trade Commission
US Generic 'Breakthrough' Pathway Could Have Unintended Consequences


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts